Last update 23 May 2025

CYT-004-MelQbG10

Overview

Basic Info

Drug Type
Virus-like particle vaccine, Therapeutic vaccine
Synonyms
Melan-A VLP vaccine, Melanoma virus-like particle vaccine, CYT 004 MelQbG10
+ [1]
Target
MAGEA1
Action
modulators
Mechanism
MAGEA1 modulators(Melanoma-associated antigen 1 modulators)
Therapeutic Areas
NeoplasmsRespiratory DiseasesSkin and Musculoskeletal Diseases
Active Indication-
Inactive Indication
HLA-A2 Positive Non-Small Cell Lung CancerMelanomaMetastatic melanoma
Originator Organization
Kuros Biosciences Ltd.Kuros Biosciences Ltd.
Active Organization-
Inactive Organization
Cytos Biotechnology AG
License Organization-
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Related

5
Clinical Trials associated with CYT-004-MelQbG10
NCT00651703
/ CompletedPhase 2
Safety, Tolerability, and Immunogenicity of CYT004-MelQbG10 Vaccine With or Without Immunostimulating Adjuvant in HLA-A2 Positive Patients With Stage III/IV Malignant Melanoma
EUCTR2005-000727-42-DE
/ Not yet recruitingNot Applicable
A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A-VLP Vaccine in HLA-A2 Positive Patients with stage III/IV Malignant Melanoma
NCT00306553
/ CompletedPhase 2
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients
100 Clinical Results associated with CYT-004-MelQbG10
Login to view more data
100 Translational Medicine associated with CYT-004-MelQbG10
Login to view more data
100 Patents (Medical) associated with CYT-004-MelQbG10
Login to view more data
100 Deals associated with CYT-004-MelQbG10
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
HLA-A2 Positive Non-Small Cell Lung CancerPhase 2
Germany
Cytos Biotechnology AG
24 Mar 2006
MelanomaPhase 2
Switzerland
Cytos Biotechnology AG
24 Mar 2006
Metastatic melanomaPhase 2
Germany
Cytos Biotechnology AG
24 Mar 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free